心臓バイオマーカー検査の世界市場レポート 2025年

心臓バイオマーカー検査の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.0％で237億5,000万米ドルに成長します。予測期間の成長は、個別化医療、心血管疾患の世界の負担増、診断における人工知能（AI）の統合、ポイントオブケア検査の拡大、疾患の早期発見の重視の高まりに起因すると考えられます。予測期間の主な動向には、技術の進歩、AI支援診断の進歩、ポイントオブケア検査（POCT）の成長、多重化機能、バイオマーカーの発見と検証が含まれます。

心血管疾患の有病率の増加が予想され、心臓バイオマーカー検査市場の成長を牽引するとみられます。心臓や血管に影響を及ぼす心血管疾患には、迅速で正確な診断ツールが必要です。心臓バイオマーカー検査は、心臓発作の重症度や程度を迅速に判断するためにバイオマーカーレベルを評価することで重要な役割を果たしています。2022年8月の米国心臓病学会（American College of Cardiology）のデータで示されたように、米国では2060年までに心血管系の危険因子や疾患の割合が大幅に増加すると予想されています。この予測は、心臓バイオマーカー検査ソリューションの需要が急増すると予測されることを強調し、心臓バイオマーカー検査市場全体の成長と一致します。

個別化医療ソリューションに対する需要の高まりは、心臓バイオマーカー検査市場を前進させる重要な促進要因として浮上しています。医療上の決定や介入を個々の患者に合わせて行う個別化医療は、より正確な循環器治療のために心臓バイオマーカー検査を取り入れることが増えています。この統合により、予防、早期発見、治療戦略が強化され、各患者の具体的なニーズに対応できるようになります。注目すべきは、2022年10月の報告によると、個別化医療ソリューションの需要拡大を反映し、75,000を超える遺伝子検査製品と300を超える個別化医薬品が大きな存在感を示していることです。この動向は、心臓バイオマーカー検査市場の持続的成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界心臓バイオマーカー検査PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の心臓バイオマーカー検査市場：成長率分析
• 世界の心臓バイオマーカー検査市場の実績：規模と成長, 2019-2024
• 世界の心臓バイオマーカー検査市場の予測：規模と成長, 2024-2029, 2034F
• 世界心臓バイオマーカー検査総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の心臓バイオマーカー検査市場バイオマーカーの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クレアチンキナーゼ（CK-MB）
• トロポニン
• ミオグロビン
• ナトリウム利尿ペプチド（BNPおよびNT-proBNP）
• 虚血修飾アルブミン（IMA）
• その他のバイオマーカーの種類
• 世界の心臓バイオマーカー検査市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• うっ血性心不全
• 急性冠症候群
• 心筋梗塞
• 動脈硬化症
• その他の用途
• 世界の心臓バイオマーカー検査市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 世界の心臓バイオマーカー検査市場クレアチンキナーゼ（CK-MB）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 総CK-MB
• CK-MB質量
• 世界の心臓バイオマーカー検査市場トロポニンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心臓トロポニンI（cTnI）
• 心臓トロポニンT（cTnT）
• 世界の心臓バイオマーカー検査市場ミオグロビンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 総ミオグロビン
• 世界の心臓バイオマーカー検査市場、ナトリウム利尿ペプチドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• B型ナトリウム利尿ペプチド（BNP）
• N末端プロB型ナトリウム利尿ペプチド（NT-ProBNP）
• 世界の心臓バイオマーカー検査市場虚血修飾アルブミン（IMA）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• IMAレベル
• 世界の心臓バイオマーカー検査市場、その他のバイオマーカータイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• C反応性タンパク質（CRP）
• 心臓型脂肪酸結合タンパク質（H-FABP）
• 可溶性ST2

第7章 地域別・国別分析

• 世界の心臓バイオマーカー検査市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の心臓バイオマーカー検査市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 心臓バイオマーカー検査市場：競合情勢
• 心臓バイオマーカー検査市場：企業プロファイル
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Thermo Fisher Scientific Inc.
• Biomerieux SA
• Becton Dickinson and Company
• Randox Laboratories Ltd.
• Enzo Biochem Inc.
• Creative Diagnostics Inc.
• Merck Co. & KGaA
• Beckman Coulter Inc.
• QIAGEN N.V.
• PerkinElmer Inc.
• Tosoh Corporation
• Eurolyser Diagnostica GmbH
• Cortez Diagnostics Inc.
• DIALAB GmbH
• CardioGenics Holdings Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 心臓バイオマーカー検査市場2029：新たな機会を提供する国
• 心臓バイオマーカー検査市場2029：新たな機会を提供するセグメント
• 心臓バイオマーカー検査市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cardiac biomarkers testing involves assessing the levels of specific substances in the blood, aiding in the diagnosis, evaluation, and monitoring of individuals possibly experiencing acute coronary syndrome (ACS).

Key biomarkers in cardiac biomarkers testing include creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), and various others. Creatine kinase (CK-MB) is an enzyme analyzed through a blood test. These tests find applications in conditions such as congestive heart failure, acute coronary syndrome, myocardial infarction, atherosclerosis, among others, primarily utilized by hospitals and specialized clinics.

The cardiac biomarkers testing market research report is one of a series of new reports from The Business Research Company that provides cardiac biomarkers testing market statistics, including cardiac biomarkers testing industry global market size, regional shares, competitors with cardiac biomarkers testing market share, detailed cardiac biomarkers testing market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac biomarkers testing industry. This cardiac biomarkers testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiac biomarkers testing market size has grown rapidly in recent years. It will grow from $13.48 billion in 2024 to $15.09 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to increasing incidence of cardiovascular diseases, aging population, awareness and education initiatives, government initiatives and healthcare policies, increasing healthcare expenditure.

The cardiac biomarkers testing market size is expected to see rapid growth in the next few years. It will grow to $23.75 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to personalized medicine, rising global burden of cardiovascular diseases, integration of artificial intelligence (ai) in diagnostics, expansion of point-of-care testing, increasing emphasis on early disease detection. Major trends in the forecast period include technological advancements, advancements in ai-assisted diagnostics, point-of-care testing (POCT) growth, multiplexing capabilities, biomarker discovery and validation.

The anticipated rise in the prevalence of cardiovascular diseases is poised to drive the growth of the cardiac biomarkers testing market. Cardiovascular diseases, impacting the heart or blood vessels, necessitate quick and accurate diagnostic tools. Cardiac biomarker tests play a crucial role by assessing biomarker levels to promptly determine the severity and magnitude of a heart attack. As indicated by data from the American College of Cardiology in August 2022, the United States is expected to witness a considerable increase in the rates of cardiovascular risk factors and diseases by the year 2060. This projection underscores the anticipated surge in demand for cardiac biomarker testing solutions, aligning with the overall growth of the cardiac biomarkers testing market.

The growing demand for personalized medical solutions emerges as a significant driver propelling the cardiac biomarkers testing market forward. Personalized medicine, tailoring medical decisions and interventions to individual patients, is increasingly incorporating cardiac biomarkers testing for more precise cardiovascular care. This integration enhances prevention, early detection, and treatment strategies, addressing the specific needs of each patient. Notably, reports from October 2022 indicate a significant presence of over 75,000 genetic testing products and 300 personalized medicines, reflecting the expanding demand for personalized medicine solutions. This trend contributes to the sustained growth of the cardiac biomarkers testing market.

Major companies in the cardiac biomarker testing market are making strides in modern cardiovascular diagnostics to enhance the early detection, accuracy, and monitoring of heart-related conditions. These advancements aim to improve test sensitivity, decrease turnaround times, and provide more comprehensive insights into heart health, ultimately leading to better patient outcomes and more effective treatment plans. For example, in October 2023, Mindray Medical International Limited, a China-based medical device company, introduced high-sensitivity troponin I (hs-cTnI) and NT-proBNP to improve the diagnosis and management of cardiovascular diseases. High-sensitivity cardiac troponin I (hs-cTnI) is a protein that enters the bloodstream when the heart muscle sustains damage. NT-proBNP is a peptide produced by the heart in response to increased ventricular volume and pressure overload. The innovative features of hs-cTnI include its ability to detect low levels of cardiac troponin, which enhances the early diagnosis of myocardial infarction, while NT-proBNP offers critical insights into the severity of heart failure through its reaction to ventricular stress. These biomarkers significantly enhance clinical decision-making and patient outcomes in cardiovascular care.

Prominent companies in the cardiac biomarker testing market are strategically focusing on innovative products, with a particular emphasis on cardiac biomarkers, to drive revenue growth. Cardiac biomarkers, also referred to as cardiac enzymes, are substances released into the bloodstream in response to heart muscle damage, serving as crucial indicators in diagnosing and monitoring cardiovascular conditions. In October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a China-based company specializing in medical equipment and solutions, launched troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTn assay surpasses minimal requirements for sensitivity, accuracy, and reliability in identifying myocardial damage. These innovative products aim to enhance treatment for cardiovascular illnesses, providing reliable solutions that improve patient outcomes both within and beyond the realm of cardiovascular diseases.

In July 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, acquired LumiraDx's Point of Care technology for an undisclosed amount. This acquisition aims to bolster Roche's diagnostic portfolio, especially in the realm of decentralized diagnostics. By incorporating LumiraDx's innovative point-of-care platform, Roche intends to enhance its capacity to deliver rapid and accurate testing at or near patient locations. LumiraDx Ltd., a healthcare company located in the UK, specializes in providing cardiac biomarker testing, including the NT-proBNP test.

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomerieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cardiac biomarkers testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiac biomarkers testing market includes revenues earned by entities by providing ischemia-modified albumin (IMA), peptides, and C-reactive protein (CRP) biomarkers testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiac Biomarkers Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiac biomarkers testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiac biomarkers testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiac biomarkers testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Biomarkers Type: Creatine Kinase (CK-MB); Troponins; Myoglobin; Natriuretic Peptides (BNP And NT-proBNP); Ischemia Modified Albumin (IMA); Other Biomarkers Types
• 2) By Application: Congestive Heart Failure; Acute Coronary Syndrome; Myocardial Infarction; Atherosclerosis; Other Applications
• 3) By End-User: Hospitals; Specialty Clinics
• Subsegments:
• 1) By Creatine Kinase (CK-MB): Total CK-MB; CK-MB Mass
• 2) By Troponins: Cardiac Troponin I (cTnI); Cardiac Troponin T (cTnT)
• 3) By Myoglobin: Total Myoglobin
• 4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP); N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)
• 5) By Ischemia Modified Albumin (IMA): IMA Levels
• 6) By Other Biomarkers Types: C-Reactive Protein (CRP); Heart-Type Fatty Acid-Binding Protein (H-FABP); Soluble ST2
• Companies Mentioned: Abbott Laboratories; Bio-Rad Laboratories Inc.; Danaher Corporation; F. Hoffmann-La Roche Ltd.; Siemens Healthineers AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cardiac Biomarkers Testing Market Characteristics

3. Cardiac Biomarkers Testing Market Trends And Strategies

4. Cardiac Biomarkers Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cardiac Biomarkers Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cardiac Biomarkers Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cardiac Biomarkers Testing Market Growth Rate Analysis
• 5.4. Global Cardiac Biomarkers Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cardiac Biomarkers Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cardiac Biomarkers Testing Total Addressable Market (TAM)

6. Cardiac Biomarkers Testing Market Segmentation

• 6.1. Global Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Creatine Kinase (CK-MB)
• Troponins
• Myoglobin
• Natriuretic Peptides (BNP and NT-proBNP)
• Ischemia Modified albumin (IMA)
• Other Biomarkers Types
• 6.2. Global Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Congestive Heart Failure
• Acute Coronary Syndrome
• Myocardial Infarction
• Atherosclerosis
• Other Applications
• 6.3. Global Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• 6.4. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Creatine Kinase (CK-MB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Total CK-MB
• CK-MB Mass
• 6.5. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Troponins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiac Troponin I (cTnI)
• Cardiac Troponin T (cTnT)
• 6.6. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Myoglobin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Total Myoglobin
• 6.7. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Natriuretic Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• B-Type Natriuretic Peptide (BNP)
• N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)
• 6.8. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Ischemia Modified Albumin (IMA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IMA Levels
• 6.9. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Other Biomarkers Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• C-Reactive Protein (CRP)
• Heart-Type Fatty Acid-Binding Protein (H-FABP)
• Soluble ST2

7. Cardiac Biomarkers Testing Market Regional And Country Analysis

• 7.1. Global Cardiac Biomarkers Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cardiac Biomarkers Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cardiac Biomarkers Testing Market

• 8.1. Asia-Pacific Cardiac Biomarkers Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cardiac Biomarkers Testing Market

• 9.1. China Cardiac Biomarkers Testing Market Overview
• 9.2. China Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cardiac Biomarkers Testing Market

• 10.1. India Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cardiac Biomarkers Testing Market

• 11.1. Japan Cardiac Biomarkers Testing Market Overview
• 11.2. Japan Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cardiac Biomarkers Testing Market

• 12.1. Australia Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cardiac Biomarkers Testing Market

• 13.1. Indonesia Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cardiac Biomarkers Testing Market

• 14.1. South Korea Cardiac Biomarkers Testing Market Overview
• 14.2. South Korea Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cardiac Biomarkers Testing Market

• 15.1. Western Europe Cardiac Biomarkers Testing Market Overview
• 15.2. Western Europe Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cardiac Biomarkers Testing Market

• 16.1. UK Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cardiac Biomarkers Testing Market

• 17.1. Germany Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cardiac Biomarkers Testing Market

• 18.1. France Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cardiac Biomarkers Testing Market

• 19.1. Italy Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cardiac Biomarkers Testing Market

• 20.1. Spain Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cardiac Biomarkers Testing Market

• 21.1. Eastern Europe Cardiac Biomarkers Testing Market Overview
• 21.2. Eastern Europe Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cardiac Biomarkers Testing Market

• 22.1. Russia Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cardiac Biomarkers Testing Market

• 23.1. North America Cardiac Biomarkers Testing Market Overview
• 23.2. North America Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cardiac Biomarkers Testing Market

• 24.1. USA Cardiac Biomarkers Testing Market Overview
• 24.2. USA Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cardiac Biomarkers Testing Market

• 25.1. Canada Cardiac Biomarkers Testing Market Overview
• 25.2. Canada Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cardiac Biomarkers Testing Market

• 26.1. South America Cardiac Biomarkers Testing Market Overview
• 26.2. South America Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cardiac Biomarkers Testing Market

• 27.1. Brazil Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cardiac Biomarkers Testing Market

• 28.1. Middle East Cardiac Biomarkers Testing Market Overview
• 28.2. Middle East Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cardiac Biomarkers Testing Market

• 29.1. Africa Cardiac Biomarkers Testing Market Overview
• 29.2. Africa Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cardiac Biomarkers Testing Market Competitive Landscape And Company Profiles

• 30.1. Cardiac Biomarkers Testing Market Competitive Landscape
• 30.2. Cardiac Biomarkers Testing Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Cardiac Biomarkers Testing Market Other Major And Innovative Companies

• 31.1. Thermo Fisher Scientific Inc.
• 31.2. Biomerieux SA
• 31.3. Becton Dickinson and Company
• 31.4. Randox Laboratories Ltd.
• 31.5. Enzo Biochem Inc.
• 31.6. Creative Diagnostics Inc.
• 31.7. Merck Co. & KGaA
• 31.8. Beckman Coulter Inc.
• 31.9. QIAGEN N.V.
• 31.10. PerkinElmer Inc.
• 31.11. Tosoh Corporation
• 31.12. Eurolyser Diagnostica GmbH
• 31.13. Cortez Diagnostics Inc.
• 31.14. DIALAB GmbH
• 31.15. CardioGenics Holdings Inc.

32. Global Cardiac Biomarkers Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiac Biomarkers Testing Market

34. Recent Developments In The Cardiac Biomarkers Testing Market

35. Cardiac Biomarkers Testing Market High Potential Countries, Segments and Strategies

• 35.1 Cardiac Biomarkers Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cardiac Biomarkers Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cardiac Biomarkers Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer